RU2011130796A - Пептиды c1orf59 и содержащие их вакцины - Google Patents
Пептиды c1orf59 и содержащие их вакцины Download PDFInfo
- Publication number
- RU2011130796A RU2011130796A RU2011130796/10A RU2011130796A RU2011130796A RU 2011130796 A RU2011130796 A RU 2011130796A RU 2011130796/10 A RU2011130796/10 A RU 2011130796/10A RU 2011130796 A RU2011130796 A RU 2011130796A RU 2011130796 A RU2011130796 A RU 2011130796A
- Authority
- RU
- Russia
- Prior art keywords
- peptide according
- amino acid
- group
- hla
- peptide
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract 38
- 102000004196 processed proteins & peptides Human genes 0.000 title claims 4
- 229960005486 vaccine Drugs 0.000 title 1
- 150000001413 amino acids Chemical group 0.000 claims abstract 18
- 239000000427 antigen Substances 0.000 claims abstract 10
- 108091007433 antigens Proteins 0.000 claims abstract 10
- 102000036639 antigens Human genes 0.000 claims abstract 10
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract 5
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims abstract 5
- 229930182817 methionine Natural products 0.000 claims abstract 5
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims abstract 4
- 239000012634 fragment Substances 0.000 claims abstract 4
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims abstract 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims abstract 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims abstract 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims abstract 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims abstract 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims abstract 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims abstract 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims abstract 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims abstract 2
- 239000004474 valine Substances 0.000 claims abstract 2
- 102000040430 polynucleotide Human genes 0.000 claims 6
- 108091033319 polynucleotide Proteins 0.000 claims 6
- 239000002157 polynucleotide Substances 0.000 claims 6
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 229940024606 amino acid Drugs 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 230000001939 inductive effect Effects 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 239000008177 pharmaceutical agent Substances 0.000 claims 3
- 108010013476 HLA-A24 Antigen Proteins 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 1
- 108091008874 T cell receptors Proteins 0.000 claims 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 1
- 210000001808 exosome Anatomy 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 229960000310 isoleucine Drugs 0.000 claims 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0635—B lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008327358 | 2008-12-24 | ||
| JP2008-327358 | 2008-12-24 | ||
| US14591209P | 2009-01-20 | 2009-01-20 | |
| US61/145,912 | 2009-01-20 | ||
| PCT/JP2009/006944 WO2010073551A1 (en) | 2008-12-24 | 2009-12-17 | C1orf59 peptides and vaccines including the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2011130796A true RU2011130796A (ru) | 2013-01-27 |
Family
ID=42287204
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011130796/10A RU2011130796A (ru) | 2008-12-24 | 2009-12-17 | Пептиды c1orf59 и содержащие их вакцины |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8735361B2 (enExample) |
| EP (1) | EP2382314A4 (enExample) |
| JP (1) | JP5728716B2 (enExample) |
| KR (1) | KR20110117112A (enExample) |
| CN (2) | CN102333867B (enExample) |
| AU (1) | AU2009332389A1 (enExample) |
| BR (1) | BRPI0923402A2 (enExample) |
| CA (1) | CA2747686A1 (enExample) |
| IL (1) | IL213318A0 (enExample) |
| MX (1) | MX2011006755A (enExample) |
| RU (1) | RU2011130796A (enExample) |
| SG (1) | SG172374A1 (enExample) |
| TW (1) | TW201030018A (enExample) |
| WO (1) | WO2010073551A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009332389A1 (en) | 2008-12-24 | 2011-07-14 | Oncotherapy Science, Inc. | C1orf59 peptides and vaccines including the same |
| WO2011161960A1 (en) * | 2010-06-23 | 2011-12-29 | Oncotherapy Science, Inc. | C1orf59 for target genes of cancer therapy and diagnosis |
| US20150359864A1 (en) | 2012-03-09 | 2015-12-17 | Oncotherapy Science, Inc. | Pharmaceutical composition containing peptides |
| US10092634B2 (en) * | 2012-09-11 | 2018-10-09 | Oncotherapy Science, Inc. | UBE2T peptides and vaccines containing the same |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997044667A2 (fr) * | 1996-05-21 | 1997-11-27 | Institut Pasteur | Methodes d'utilisation de complexes peptide/complexe majeur d'histocompatibilite pour obtenir ou purifier des cellules t antigene-specifiques et pour stimuler des cellules t |
| CN1280307C (zh) * | 2001-04-03 | 2006-10-18 | 宝生物工程株式会社 | 细胞毒性t淋巴细胞 |
| US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| EP1453471B1 (en) | 2001-11-07 | 2011-01-05 | Mannkind Corporation | Expression vectors encoding epitopes of antigens and methods for their design |
| US7514084B2 (en) * | 2002-09-12 | 2009-04-07 | Oncotherapy Science, Inc. | KDR peptides and vaccines comprising the same |
| TWI324608B (en) | 2003-02-28 | 2010-05-11 | Oncotherapy Science Inc | Genes and polypeptides relating to human colorectal cancers |
| WO2005005631A1 (ja) * | 2003-07-11 | 2005-01-20 | Dainippon Sumitomo Pharma Co., Ltd. | リビン由来のｈｌａ-ａ２４結合性癌抗原ペプチド |
| JP4628208B2 (ja) * | 2004-08-10 | 2011-02-09 | オンコセラピー・サイエンス株式会社 | Ｃｘａｄｒｌ１またはｇｃｕｄ１タンパク質を発現する胃癌または結腸直腸癌の治療のためのペプチドワクチン |
| KR20080013850A (ko) * | 2005-02-08 | 2008-02-13 | 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 | 면역원성 분자 |
| PT2325305E (pt) | 2005-02-25 | 2014-04-29 | Oncotherapy Science Inc | Vacinas peptídicas para cancros do pulmão que expressam polipéptidos ttk, urlc10 ou koc1 |
| CN1948342B (zh) * | 2005-10-14 | 2010-12-29 | 中国人民解放军第二军医大学 | 一种新的候选癌基因hRabJ来源的HLA-A2限制性表位多肽及其应用 |
| TWI441648B (zh) * | 2007-01-03 | 2014-06-21 | Oncotherapy Science Inc | Ｆｏｘｐ３胜肽疫苗 |
| CA2676090A1 (en) * | 2007-02-06 | 2008-10-02 | Genizon Biosciences Inc. | Genemap of the human genes associated with adhd |
| TWI596109B (zh) * | 2007-02-21 | 2017-08-21 | 腫瘤療法 科學股份有限公司 | 表現腫瘤相關抗原之癌症的胜肽疫苗 |
| AU2009332389A1 (en) | 2008-12-24 | 2011-07-14 | Oncotherapy Science, Inc. | C1orf59 peptides and vaccines including the same |
-
2009
- 2009-12-17 AU AU2009332389A patent/AU2009332389A1/en not_active Abandoned
- 2009-12-17 CN CN200980157412.3A patent/CN102333867B/zh not_active Expired - Fee Related
- 2009-12-17 SG SG2011046497A patent/SG172374A1/en unknown
- 2009-12-17 KR KR1020117017449A patent/KR20110117112A/ko not_active Withdrawn
- 2009-12-17 CN CN201410336021.0A patent/CN104193816A/zh active Pending
- 2009-12-17 WO PCT/JP2009/006944 patent/WO2010073551A1/en not_active Ceased
- 2009-12-17 RU RU2011130796/10A patent/RU2011130796A/ru not_active Application Discontinuation
- 2009-12-17 BR BRPI0923402-0A patent/BRPI0923402A2/pt not_active IP Right Cessation
- 2009-12-17 JP JP2011527091A patent/JP5728716B2/ja not_active Expired - Fee Related
- 2009-12-17 EP EP09834363A patent/EP2382314A4/en not_active Withdrawn
- 2009-12-17 US US13/141,389 patent/US8735361B2/en not_active Expired - Fee Related
- 2009-12-17 CA CA2747686A patent/CA2747686A1/en not_active Abandoned
- 2009-12-17 MX MX2011006755A patent/MX2011006755A/es active IP Right Grant
- 2009-12-22 TW TW098144135A patent/TW201030018A/zh unknown
-
2011
- 2011-06-02 IL IL213318A patent/IL213318A0/en unknown
-
2014
- 2014-03-06 US US14/199,784 patent/US20140199335A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP5728716B2 (ja) | 2015-06-03 |
| SG172374A1 (en) | 2011-07-28 |
| AU2009332389A1 (en) | 2011-07-14 |
| US20120003253A1 (en) | 2012-01-05 |
| EP2382314A1 (en) | 2011-11-02 |
| CN102333867A (zh) | 2012-01-25 |
| TW201030018A (en) | 2010-08-16 |
| JP2012513742A (ja) | 2012-06-21 |
| BRPI0923402A2 (pt) | 2015-08-04 |
| KR20110117112A (ko) | 2011-10-26 |
| US8735361B2 (en) | 2014-05-27 |
| CN104193816A (zh) | 2014-12-10 |
| MX2011006755A (es) | 2011-07-20 |
| EP2382314A4 (en) | 2013-03-06 |
| WO2010073551A1 (en) | 2010-07-01 |
| CN102333867B (zh) | 2015-01-14 |
| CA2747686A1 (en) | 2010-07-01 |
| IL213318A0 (en) | 2011-07-31 |
| US20140199335A1 (en) | 2014-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2009141595A (ru) | Пептиды тем8 и содержащие их вакцины | |
| RU2011110504A (ru) | Эпитопные пептиды inhbb и вакцины, содержащие данные пептиды | |
| RU2011138160A (ru) | Пептиды foxmi и вакцины, содержащие их | |
| JP2010506826A5 (enExample) | ||
| JP2010523471A5 (enExample) | ||
| RU2010154081A (ru) | Эпитопные пептиды iqgap3 вакцины, содержащие их | |
| RU2011101709A (ru) | Cdca1 эпитоп-пептиды и содержащие их вакцины | |
| RU2013112616A (ru) | Пептид cdca1 и включающее его фармацевтическое средство | |
| JP2008530975A5 (enExample) | ||
| JP2012517799A5 (enExample) | ||
| JP2011524737A5 (enExample) | ||
| RU2010110545A (ru) | Cdh3-пептид и включающее его лекарственное средство | |
| RU2012127358A (ru) | Олигопептиды imp-3 и содержащие их вакцины | |
| RU2010154101A (ru) | Пептиды эпитопов mybl2 и содержащие их вакцины | |
| RU2009129531A (ru) | Вакцины на основе пептида foxp3 | |
| RU2012136464A (ru) | Модифицированные пептиды melk и содержащие их вакцины | |
| RU2014121502A (ru) | Пептиды торк и содержащие их вакцины | |
| RU2013158399A (ru) | Пептиды sema5b и содержащие их вакцины | |
| RU2012147590A (ru) | Пептиды cdca5 и содержащие их вакцины | |
| RU2010126154A (ru) | Эпитопные пептиды stat3 | |
| RU2015113436A (ru) | Пептиды ube2t и содержащие их вакцины | |
| RU2014109137A (ru) | Пептиды mphosph1 и вакцины, включающие их | |
| JP2015529219A5 (enExample) | ||
| JP2011529683A5 (enExample) | ||
| RU2011130796A (ru) | Пептиды c1orf59 и содержащие их вакцины |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20160322 |